A new Flagship Pioneering startup has emerged with $200 million and a team of experts in both science and AI to pursue what ...

BioNTech has forecast lackluster sales for 2025 despite ending last year on a relatively strong note, causing the drugmaker’s ...

Emergent BioSolutions sells Baltimore facility to Syngene International for $36.5M; site previously mixed J&J and AstraZeneca ...

The FDA told staff on Monday that reviewers of medical products and inspectors of manufacturing facilities cannot take the ...

Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide ...

Beam Therapeutics said its experimental gene editing treatment helped lower levels of mutant proteins and increase levels of ...

Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are ...

Trevi's Haduvio reduces chronic cough by 57% vs placebo in Phase 2a trial, surpassing expectations. Stock rises 40%.

Arrowhead Pharmaceuticals on Monday shared new open-label data in about a dozen patients for a program designed to improve ...

After months of searching for a partner for its recently approved cancer drug, Checkpoint Therapeutics has instead secured a ...

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the ...

Mineralys Therapeutics' lorundrostat shows promising Phase 3 results in treating resistant hypertension, with 9.1 mmHg blood ...